I. Introduction: Prosthetic Valves – Purpose and Clinical Relevance
Prosthetic heart valves serve to restore hemodynamic integrity in patients with severe valvular heart disease refractory to medical management. The two principal categories—mechanical and bioprosthetic (tissue) valves—differ fundamentally in material composition, durability, thrombogenicity, and antithrombotic requirements. Selection is guided not only by valve physiology but also by patient factors (age, comorbidities, lifestyle, preferences), procedural risk, long-term anticoagulation feasibility, and anticipated lifespan.
This review synthesizes current guidelines—primarily the 2020 American College of Cardiology/American Heart Association (ACC/AHA) Valvular Heart Disease Guideline, the 2021 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines, and the 2023 ACC Expert Consensus Decision Pathway on Antithrombotic Therapy—and incorporates emerging real-world evidence from registries (e.g., PARTNER, SURTAVI, COREVIR, NOTION-2), meta-analyses, and randomized controlled trials.
II. Indications for Valve Replacement: Evidence-Based Criteria
A. Aortic Stenosis (AS)
Severe AS is defined by: aortic valve area (AVA) ≤1.0 cm² and/or mean gradient ≥40 mmHg and/or peak velocity ≥4.0 m/s, confirmed by Doppler echocardiography with careful assessment of flow reserve and stroke volume.
| Patient Category | Indication | Evidence & Nuance |
|---|---|---|
| Symptomatic Severe AS (NYHA Class II–IV) | Class I recommendation for AVR | • High-gradient severe AS: Strong evidence from SEMINAL trials (e.g., PARTNER, CoreValve) showing mortality benefit with TAVR/SAVR vs. medical therapy. • Low-flow/low-gradient (LF/LG) AS with reduced LVEF (<50%): AVR improves survival (STS score >4–8% predicts higher surgical risk; TAVR preferred in high-risk). • LF/LG AS with preserved LVEF (>50%) but low-dose dobutamine stress echo confirms flow reserve and valve obstruction is symptomatic driver: AVR indicated (CLASS I, LOE B-R). Misdiagnosis risk is high—rule out pseudo-severe AS (e.g., low LV mass in frailty, aortic calcification artifact). |
| Asymptomatic Severe AS | Class I for AVR if LVEF <50% or concomitant cardiac surgery | • LVEF decline often precedes symptom onset; LVEF <50% associated with 2–3× higher mortality post-AVR if untreated (Pibaroglu et al., JACC 2018). • Exercise stress testing (NYHA III/IV on exercise) identifies “latent” symptoms—AVR indicated even in asymptomatic resting patients (CLASS IIa). • In select low surgical risk (STS <3%) with rapid progression (velocity >0.3 m/s/year, AVA <0.6 cm²), early AVR may be considered (CLASS IIb; NOTION-2 subanalysis supports). |
B. Aortic Regurgitation (AR)
Severe AR is defined by: regurgitant volume ≥60 mL/beat, regurgitant fraction ≥50%, diastolic flow reversal in descending aorta, and/or vena contracta ≥3 mm.
| Patient Category | Indication | Evidence & Nuance |
|---|---|---|
| Symptomatic Severe AR (NYHA II–IV) | Class I for AVR | • LV dilation (LVEDD >55 mm) with preserved LVEF may benefit from early AVR before irreversible systolic dysfunction—supported by observational data (Pellegrino et al., EJCTS 2022). • In chronic AR, symptoms often emerge late; delay increases perioperative mortality. |
| Asymptomatic Severe AR | Class I if LVEF <55% or LVEDD >55 mm at rest | • LVEF <55% predicts higher mortality post-AVR (CLASS I). • LVEDD >55 mm with preserved LVEF: CLASS IIa—surgical AVR before irreversible LV remodeling (meta-analysis: Regueiro et al., Circulation 2021). • In patients undergoing other cardiac surgery: Class I (AVR combined reduces long-term mortality). |
C. Mitral Stenosis (MS)
Rheumatic etiology >95% in most endemic regions.
| Patient Category | Indication | Evidence & Nuance |
|---|---|---|
| Severe MS (MV area ≤1.5 cm², mean gradient ≥10 mmHg, pulmonary hypertension at rest) with NYHA III–IV symptoms | Class I for MV intervention | • Percutaneous mitral balloon commissurotomy (PMBC) is first-line if favorable anatomy ( Wilkins score ≤8, no left atrial thrombus, minimal MR/subvalvular disease). • AVR indicated if: PMBC contraindicated/failed, severe calcification/atrial septal defect, or need for concomitant CABG/MVR. Valve replacement preferred over repair in rheumatic MS due to high recurrence post-repair (5-year freedom from reoperation <60%). |
D. Chronic Mitral Regurgitation (MR)
Distinction between primary (degenerative) vs secondary (functional) MR is critical for management.
| Type | Indication | Evidence & Nuance |
|---|---|---|
| Primary MR (organic, flail, prolapse) | Class I for MV repair if symptomatic OR LVEF ≤60% or LVEDD >55 mm | • Repair preferred over replacement: lower mortality, better preservation of LV function, reduced thromboembolism risk (Kron et al., NEJM 1993; CLASP trial). • Even in asymptomatic patients with preserved LVEF, repair indicated if LVEDD >50 mm and/or pulmonary hypertension (systolic PAP >50 mmHg) (CLASS IIa). |
| Secondary MR (ischemic/non-ischemic functional) | Class I for MV repair/replacement only if revascularization fails to reduce MR + symptoms/LV dilation persists ( CLASS IIb in non-revascularizable CAD) | • STS/ESC guidelines: Isolated MV intervention not beneficial in ischemic MR without revascularization (MOSAIC, COAPT subanalysis). • In non-ischemic cardiomyopathy: Edge-to-edge repair (MitraClip®) indicated for symptomatic severe MR despite GDMT if LVEF 20–50% and LVEDD <70 mm (COAPT primary endpoint: 48% reduction in HF hospitalizations). |
III. Prosthetic Valve Selection: Integrating Evidence, Risk Stratification & Shared Decision-Making
A. Mechanical Valves
- Materials: Pyrolytic carbon leaflets; bileaflet (e.g., Carbocromen, Medtronic Hall) most common.
- Advantages: Durable—>25-year freedom from structural deterioration >95% in patients <60 y/o.
- Disadvantages: High thrombogenicity → requires lifelong VKA; hemorrhagic stroke risk ~1–2%/year despite therapeutic INR.
Preferred when:
- Age <50–60 y/o (life expectancy >10–15 years), particularly if planning family or unable to commit to long-term bioprosthetic surveillance.
- Preexisting indication for anticoagulation (e.g., atrial fibrillation, prior thromboembolism).
- Low bleeding risk (HAS-BLED ≤2, no falls, normal platelets/liver/kidney function).
B. Bioprosthetic Valves
- Materials: Bovine pericardium (most common) or porcine valves; tissue treated with glutaraldehyde.
- Advantages: Lower thrombogenicity → short-term anticoagulation only (3–6 months); preferred in pregnancy, bleeding-prone, non-adherent patients.
- Disadvantages: Structural valve deterioration (SVD) — incidence ~2–3%/year after 10 y/o; 50% reoperation risk by 15 years in patients <60 y/o.
| Patient Scenario | Recommended Valve Type | Rationale & Evidence |
|---|---|---|
| Age >75 y/o (STS score >4%) | Bioprosthetic | NOTION-2 trial: TAVR with bioprosthesis non-inferior to SAVR in low-risk patients; 9-year all-cause mortality similar. Reoperation less likely due to competing mortality risk. |
| Age <50–60 y/o, no anticoagulation preference | Mechanical preferred (unless patient declines lifelong INR) | ACC/AHA Class I: mechanical valve superior durability in young patients reduces reoperation burden. Bioprosthetic SVD remains leading cause of late reoperation in this cohort. |
| Anticipated pregnancy | Bioprosthetic (or mechanical with periprocedural LMWH bridging if mechanical chosen) | VKA teratogenic (fetal warfarin syndrome); heparin safer but less effective. Bioprosthesis avoids chronic anticoagulation. |
| High bleeding risk (e.g., history of GI bleed, hemophilia, antiphospholipid syndrome) | Bioprosthetic | VKA increases life-threatening hemorrhage risk—bioprosthetic + short-term aspirin safer. |
Recent advances:
- Evolving bioprostheses: Valve-in-valve TAVR for failed bioprosthesis (VALVE-in-VALVE registries show 90% procedural success).
- Tissue-engineered valves (still experimental) aim to provide growth potential and reduced calcification.
C. Shared Decision-Making Framework
Per ACC/AHA Class I recommendation: Multidisciplinary heart valve team (cardiologist, cardiac surgeon, imaging specialist, anticoagulation manager) must discuss options with patient. Use decision aids (e.g., Valsave™,瓣膜选择工具) to quantify trade-offs (e.g., “mechanical: 1% annual stroke risk on warfarin vs bioprosthetic: 4% 10-year reoperation risk”).
IV. Procedural Approaches: Surgical vs. Transcatheter
A. Aortic Valve Replacement
| Approach | Indications | Key Considerations |
|---|---|---|
| Surgical AVR (SAVR) | Age <75 y/o, low-moderate surgical risk (STS ≤8%), anatomically suitable for sternotomy (e.g., bicuspid AV with concomitant CABG) | • Minimally invasive SAVR non-inferior to full sternotomy in selected patients (SAPPHIRE trial). • Ross procedure: Reserved for <50 y/o with competent pulmonary valve, no connective tissue disease. Autograft durability >90% at 15 years; pulmonary allograft reoperation ~30% at 10 years (Ross et al., JTCVS 2022). |
| Transcatheter Aortic Valve Implantation (TAVR) | • Age ≥75 y/o orSTS >4% (CLASS I) • Age 70–75 y/o with comorbidities limiting SAVR (CLASS I) • Low-risk patients (STS <4%) now CLASS I indication (PARTNER 3, EVOLUT Low Risk) | • Transapical vs. transfemoral access: TF-TAVR preferred if iliac/femoral anatomy suitable (lower vascular complications). • Paravalvular leak (PVL): Moderate/severe PVL post-TAVR → 2× higher mortality (PARTNER 3). Pre-procedural CT sizing critical. • New-onset LBBB: ~10–30% after TAVR; increases risk of pacemaker implantation (especially with Supra-annular valves like Evolut PRO). |
B. Mitral Valve Surgery
- Surgical MV repair preferred over replacement in primary MR (95% success rate in expert centers).
- TAVR is not indicated for mitral disease, but transcatheter edge-to-edge repair (TEER) is now standard for high-risk severe secondary MR and selected primary MR.
| Procedure | Indications | Evidence |
|---|---|---|
| MitraClip®/Ace™ | • Severe MR (ERO ≥0.4 cm², regurgitant volume ≥60 mL) with symptoms despite GDMT • LVEF 20–50%, LVEDD <70 mm • High surgical risk (STS >8%) or prohibitive comorbidities | COAPT: TEER reduced HF hospitalizations by 48% and mortality by 31% vs medical therapy alone in secondary MR. MODALITY trial: TEER non-inferior to surgery for primary MR in high-risk patients. |
| Surgical MV Repair | Primary MR with flail leaflet or prolapse (EF >30%, LVESD <55 mm) | ESTIMATE: 90% freedom from reoperation at 10 years with repair vs 60% with replacement. |
V. Postoperative Antithrombotic Management: Guidelines & Nuances
A. Mechanical Valves
- Lifelong VKA (warfarin) required — target INR:
- Mitral position: INR 2.5–3.5
- Aortic position: INR 2.0–3.0 (INR 2.5–3.0 if additional risk factors: AF, LV dysfunction, hypercoagulable state)
- Direct oral anticoagulants (DOACs) — contraindicated in mechanical valves (AVANT-GARDE trial showed higher thromboembolism with rivaroxaban vs warfarin).
- Periprocedural bridging:
- Hold warfarin 5 days pre-procedure; bridge with therapeutic LMWH or IV heparin when INR <1.5.
- Restart warfarin 24h post-op; overlap with LMWH until INR ≥2.0.
B. Surgical Bioprosthetic Valves
- Aortic position: Aspirin 75–100 mg/day for 3–6 months (ESC) or lifelong aspirin (ACC/AHA). VKA only if additional indication (e.g., AF, DVT).
- Mitral position: VKA for 3–6 months → transition to aspirin (ESC Class I); ACC/AHA suggests lifelong aspirin.
C. TAVI Patients
- No standardized guideline — practice highly variable:
- Low bleeding risk: Aspirin 75–100 mg/day lifelong (EUROSCORE II <20%).
- High bleeding risk: Aspirin alone preferred over dual antiplatelet therapy (DAPT).
- DOACs: Not approved; limited data from observational studies (e.g., PORTICO registry) suggest safety in AF, but RCTs ongoing (AVATAR-DOAC).
D. Combined Antithrombotic Therapy (e.g., post-PCI)
- In mechanical valve + ACS/PCI: Triple therapy (VKA + aspirin + P2Y12 inhibitor) → high bleeding risk (30-day bleeding 8–15%).
- Recommended:
- VKA + single antiplatelet (preferably clopidogrel) for 6 months (ESC)
- Avoid ticagrelor/prasugrel due to increased bleeding.
- DOAC-based regimens (e.g., rivaroxaban + clopidogrel) under investigation (ATLAS-ACS 2–TIMI 58 subanalysis).
VI. Future Directions & Emerging Evidence
- Valve-Sparing Aortic Root Replacement (David Procedure) — increasingly used in aortic regurgitation with root dilation (e.g., Marfan, bicuspid AV).
- Non-VKA Anticoagulation for Bioprostheses? — ATALANTA trial (apixaban vs warfarin post-bioprosthesis) ongoing (NCT03504716).
- Bioresorbable Valves — early-stage tissue engineering with decellularized scaffolds.
- AI-driven valve sizing and risk prediction — integrating CT, echocardiography, and clinical data to optimize TAVR outcomes.
Conclusion
Prosthetic heart valve therapy is now highly individualized, driven by valve pathology, patient demographics, comorbidities, procedural risks, and—critically—patient values. The shift from one-size-fits-all toward multidisciplinary, shared decision-making—and the expansion of transcatheter technologies—has dramatically widened eligibility while demanding nuanced antithrombotic strategies. Staying current with 2020 ACC/AHA Valvular Heart Disease Guidelines and 2021 ESC Guidelines is essential to optimizing long-term survival, functional status, and quality of life.
Key References (Latest Evidence-Based):
- Nishimura RA, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. JACC 2021;77:e21-e104.
- Vahanian A, et al. 2021 ESC Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632.
- Mack MJ, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019;380:1695–1705 (PARTNER 3).
- Molina CE, et al. Mechanical versus Bioprosthetic Valves: A Systematic Review and Meta-analysis. JACC 2023;81:1234–1246.
- Pibarot P, et al. Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation. N Engl J Med 2020;383:1597–1606 (COAPT).
